Patents Examined by Sandra Wegert
-
Patent number: 8440788Abstract: The present invention relates generally to variants and peptides of the mitochondrial protein, voltage-dependent anion channel (VDAC) and to polynucleotides encoding same. In particular, the present invention is directed to N-terminal truncated and mutated VDAC and specific amino acid and polynucleotide sequences thereof useful in inhibiting apoptosis, and to pharmaceutical compositions comprising same useful in the treatment of diseases associated with excess apoptosis.Type: GrantFiled: April 10, 2007Date of Patent: May 14, 2013Assignee: Ben-Gurion University of The Negev Research and Development Authority Ltd.Inventors: Varda Shoshan-Barmatz, Doron Calo
-
Patent number: 8398984Abstract: The present invention is to provide a removal promoter for apoptotic cells which is capable of immediately removing apoptotic cells in vivo by macrophages, or a removal inhibitor which inhibits the removal of apoptotic cells in vivo by macrophages. A removal promoter for apoptotic cells in vivo containing the milk fat globule-EGF factor 8-L (MFG-E8-L), MFG-E8-L mutant having removal promotion action for apoptotic cells in vivo by macrophages, or preferably a recombinant human or mouse MFG-E8-L, or a recombinant human or mouse MFG-E8-L mutant as an active ingredient is prepared. Such removal promoters specifically bind to apoptotic cells and promote the phagocytosis of apoptotic cells by macrophages by recognizing aminophospholipids such as phosphatidylserine exposed on apoptotic cell surface. On the other hand, a point mutation (D89E) MFG-E8-L mutant is used as a removal inhibitor.Type: GrantFiled: September 30, 2009Date of Patent: March 19, 2013Assignee: Japan Science and Technology AgencyInventor: Shigekazu Nagata
-
Patent number: 8394929Abstract: Disclosed are NgR proteins and biologically active Nogo (ligand) protein fragments. Also disclosed are compositions and methods for modulating the expression or activity of the Nogo and NgR protein. Also disclosed are peptides which block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in the treatment of cranial or cerebral trauma, spinal cord injury, stroke or a demyelinating disease.Type: GrantFiled: January 26, 2010Date of Patent: March 12, 2013Assignee: Yale UniversityInventor: Stephen M. Strittmatter
-
IGF-1R specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
Patent number: 8344112Abstract: The present invention relates to mammalian antibodies, designated 12B1 and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), preferably human IGF-IR. Also included are chimeric, bispecific, derivatized, single chain antibodies derived from the antibodies disclosed herein. Nucleic acid molecules encoding the mammalian antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with expression of IGF-1R.Type: GrantFiled: July 25, 2008Date of Patent: January 1, 2013Assignee: Merck Sharp & Dohme LimitedInventors: Liliane Goetsch, David Brooks, Michael Chastain, Zhi-Qiang Zhang, Nathalie Corvaia -
Patent number: 8329866Abstract: Disclosed are polymer sFlt-1 conjugates, variants of sFlt-1, compositions comprising such conjugates and variants, including cysteine variants of sFlt-1. Also disclosed is the use of such conjugates, variants and compositions in methods to inhibit the activity of VEGF, to inhibit angiogenesis, and to treat or reduce at least one symptom of diseases and conditions in which it is desirable to inhibit VEGF activity and/or angiogenesis.Type: GrantFiled: October 3, 2006Date of Patent: December 11, 2012Assignee: Bolder Biotechnology, Inc.Inventors: Mary S. Rosendahl, George N. Cox, III
-
Patent number: 8318910Abstract: This invention relates to monoclonal and polyclonal antibodies capable of specifically recognizing IL-13 receptor ? and uses thereof.Type: GrantFiled: February 15, 2011Date of Patent: November 27, 2012Assignee: SanofiInventors: Daniel Caput, Pascual Ferrara, Patrick Laurent, Natalio Vita
-
Patent number: 8313745Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.Type: GrantFiled: June 8, 2010Date of Patent: November 20, 2012Assignee: Abbott Biotherapeutics Corp.Inventors: David Mack, Kurt C. Gish
-
Patent number: 8309701Abstract: Identified herein are different forms of bitter receptor genes that occur in different humans. These alleles are generated by numerous coding single nucleotide polymorphisms (cSNP's) that occur within the members of the T2R gene family. Some SNP's cause amino acid substitutions, while others introduce chain termination codons, rendering the allele non-functional. Differences in these genes are believed to have a large effect on those individuals' sense of bitter taste, such that these individuals perceive the taste of bitter substances differently than the rest of the population. The ability to assay this allelic information is useful in the development of flavorings and flavor enhancers, as it can be used to define large groups and populations who perceive bitter tastes differently. This in turn allows the taste preferences of these groups to be addressed at the molecular level for the first time.Type: GrantFiled: August 3, 2009Date of Patent: November 13, 2012Assignee: The United States of America as represented by the Secrectary of the Department of Health and Human ServicesInventors: Dennis Drayna, Un-Kyung Kim
-
Patent number: 8257934Abstract: The present invention provides nucleic acids encoding a novel ABC family cholesterol transporter, SSG. The herein-disclosed sequences can be used for any of a number of purposes, including for the diagnosis and treatment of cholesterol-associated disorders, including sitosterolemia, and for the identification of molecules that associate with and/or modulate the activity of SSG.Type: GrantFiled: February 12, 2010Date of Patent: September 4, 2012Assignee: Amgen Inc.Inventors: Hui Tian, Joshua Schultz, Bei Shan
-
Patent number: 8227575Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.Type: GrantFiled: November 25, 2009Date of Patent: July 24, 2012Assignee: ZymoGenetics, Inc.Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
-
Patent number: 8211666Abstract: Nucleic acid and protein sequences relating to a cation channel which is sperm-specific (CatSper1) are disclosed. The CatSper1 protein is shown to be specifically expressed in sperm and to be necessary for sperm motility. Nucleic acids, vectors, transformed cells, transgenic animals, polypeptides, and antibodies relating to the CatSper1 gene and protein are disclosed. Also provided are methods of in vitro fertilization and contraception, methods of identifying modulators of CatSper1 activity, methods of genotyping subjects with respect to CatSper1, and methods of diagnosing and treating CatSper1-mediated disorders, including infertility.Type: GrantFiled: October 30, 2003Date of Patent: July 3, 2012Assignee: Children's Medical Center CorporationInventors: David E. Clapham, Dejian Ren
-
Patent number: 8163877Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Dermacentor variabilis ligand gated ion channel proteins. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding D. variabilis LGIC/GluCl channels, substantially purified forms of associated D. variabilis channel proteins and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Dermacentor variabilis LGIC/GluCl, which will be useful as insecticides and acaricides.Type: GrantFiled: January 8, 2010Date of Patent: April 24, 2012Assignee: Merial LimitedInventors: Doris F. Cully, Yingcong Zheng
-
Patent number: 8138317Abstract: The invention is a method for the purification of mono-PEGylated erythropoietin using two cation exchange chromatography steps wherein the same type of cation exchange material is used in both cation exchange chromatography steps and a method for producing a mono-PEGylated erythropoietin in substantially homogeneous form.Type: GrantFiled: July 16, 2008Date of Patent: March 20, 2012Assignee: Hoffmann-La Roche Inc.Inventors: Josef Burg, Klaus Reichert, Axel Schroth, Hartmut Schurig, Axel Wessner
-
Patent number: 8133974Abstract: Positional cloning has been carried out to identify the gene responsible for the hypochromic anemia of the zebrafish mutant weissherbst. The gene, ferroportin1, encodes a novel multiple-transmembrane domain protein, expressed in the yolk sac. Zebrafish ferroportin1 is required for the transport of iron from maternally-derived yolk stores to the circulation, and functions as an iron exporter when expressed in Xenopus oocytes. Human and mouse homologs of the ferroportin1 gene have been identified. The invention includes isolated polynucleotides, vectors and host cells comprising nucleotide sequences encoding Ferroportin1 proteins and variants thereof, including those having iron transport function. The invention also includes polypeptides encoded by ferroportin1 genes and variants of such polypeptides, and fusion polypeptides comprising a Ferroportin1 or a portion thereof.Type: GrantFiled: March 16, 2009Date of Patent: March 13, 2012Assignee: Children's Medical Center CorporationInventors: Leonard I. Zon, Adriana Donovan
-
Patent number: 8030456Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same.Type: GrantFiled: December 15, 2008Date of Patent: October 4, 2011Assignees: Yale University, Biogen Idec MA Inc.Inventors: Daniel H. S. Lee, R. Blake Pepinsky, Weiwei Li, Jane K. Relton, Dane S. Worley, Stephen M. Strittmatter, Dinah W. Y. Sah, Sylvia A. Rabacchi
-
Patent number: 8017343Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.Type: GrantFiled: October 19, 2006Date of Patent: September 13, 2011Assignee: ZymoGenetics, Inc.Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
-
Patent number: 7973139Abstract: The present invention relates to antibodies and related molecules that specifically bind to the Nogo receptor (NogoR). Such antibodies have uses, for example, in the treatment of spinal cord injury, brain trauma, paralysis, degenerative nervous system diseases, and stroke. The invention also relates to nucleic acid molecules encoding anti-NogoR antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same.Type: GrantFiled: March 25, 2005Date of Patent: July 5, 2011Assignee: Human Genome Sciences, Inc.Inventors: Adam Bell, Craig A. Rosen
-
Patent number: 7910705Abstract: A line of cultured mammalian cells includes HERG1b subunits and optionally HERG1a subunits.Type: GrantFiled: February 18, 2009Date of Patent: March 22, 2011Assignee: Wisconsin Alumni Research FoundationInventors: Gail A. Robertson, Eugenia M. Jones, Jinling Wang
-
Patent number: 7879092Abstract: The present invention relates to a dental implant having recombinant bone morphogenic protein coated on the processed surface thereof, which, when implanted into the jawbone, enables undifferentiated adult cells around the implant site to be rapidly differentiated into osteoblasts so as to induce osteoconductive healing to thereby reduce a healing period, as well as a coating method thereof. According to the invention, recombinant bone morphogenic protein BMP-2 penetrates between ceramic balls formed on the dental implant surface, sheet structures of calcium triphosphate or fine pores formed by anodic oxidation, so as to form a coating film. Thus, the recombinant bone morphogenic protein BMP-2 is not detached from the dental implant surface even during the surgical implantation of the implant.Type: GrantFiled: October 19, 2006Date of Patent: February 1, 2011Assignees: Cowellmedi Co., LtdInventor: Soo Hong Kim
-
Patent number: 7785593Abstract: This invention relates to molecules, such as for example monoclonal antibodies or Fab fragments thereof, which are capable of binding to the human NogoA polypeptide or human NiG or human NiG- or human NogoA_623-640 with a dissociation constant <1000 nM; polynucleotides encoding such a binding molecule; an expression vector comprising such polynucleotides; the use of such a binding molecule in the treatment of nerve repair, a pharmaceutical composition comprising such a binding molecule; and to a method of treatment of diseases associated with nerve repair.Type: GrantFiled: December 9, 2003Date of Patent: August 31, 2010Assignees: Novartis AG, University of ZurichInventors: Carmen Barske, Anis Khusro Mir, Thomas Oertle, Lisa Schnell, Martin E. Schwab, Alessandra Vitaliti, Mauro Zurini